Abstract
Background:Patients on immunosuppressive therapy are at a greater risk for herpes zoster reactivation and are more likely to have adverse outcomes. Propylactic antivrials and vaccinations may potentially prevent these complications.Methods: Medical literature addressing the clinical course and therapy of herpes zoster in patients receiving immunosuppressive therapy for autoimmune disorders, and the roles of anti-viral prophylaxis and vaccination was reviewed. Research databases including PubMed, Ovid, Medline, Google Scholar and Cochrane were utilized.Results: Acyclovirand its derivativesare most commonly used in this setting for treatment and reduction of post-zostercomplications. Foscarnet may be used for acyclovir-resistant strains. At both conventional and ultra-low doses, acyclovir has proven effective when used as prophylaxis, reducing the incidence of zoster and its complications in immunosuppressed patients. Additionally, ultra-low doses are associated with significantly reduced side effects. The zoster vaccine, Zostavax, a live-attenuated vaccine has shown promising results in several clinical trials. However, live-attenuated vaccines should be cautiously used in immunosuppressed patients. For patients who require immunosuppressive therapy, vaccination 2–3 months prior to therapy may be appropriate.Conclusions: Prophylactic antiviral therapy and vaccination help significantly reduce morbidity and mortality from zoster reactivation in patients receiving immunosuppressive therapy.
Mohammad Faizan Zahid, Mariam Ghufran, Armaghan-e-Rehman , Muhammad Rizwan Sohail. (2017) HERPES ZOSTER DURING IMMUNOSUPPRESSIVE THERAPY FOR AUTOIMMUNE DISEASES, JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD, Volume 29, Issue 3.
-
Views
499 -
Downloads
43
Article Details
Volume
Issue
Type
Language
